<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948035</url>
  </required_header>
  <id_info>
    <org_study_id>DSMM XVII</org_study_id>
    <secondary_id>2017-001616-11</secondary_id>
    <nct_id>NCT03948035</nct_id>
  </id_info>
  <brief_title>Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM</brief_title>
  <official_title>Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a&#xD;
      lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III&#xD;
      trials in MM patients. One phase III trial in MM patients with one to three prior lines of&#xD;
      therapy compared elotuzumab-Rd with standard Rd. The triple combination was shown to&#xD;
      significantly prolong PFS in this patient cohort with a greater proportion of patients in at&#xD;
      least very good partial response (VGPR) when compared to subjects on Rd. Notably, the rate of&#xD;
      infusion-related reactions with this specific moAb was very low, with an overall rate of 10%&#xD;
      in premedicated patients and only 1% of Grade 3 severity. Grades 4/5 infusion-related&#xD;
      reactions were absent and only 1% of patients on elotuzumab discontinued for infusion-related&#xD;
      reactions. Of particular interest is the observation in this trial, that response and PFS&#xD;
      were independent of cytogenetic high-risk features, i.e., deletion of chromosome 17p and&#xD;
      translocation t(4;14). This effect distinguishes elotuzumab from most, if not all, other&#xD;
      drug-based approaches.&#xD;
&#xD;
      The investigators assume that incorporating the moAb into the KRd triple induction regimen&#xD;
      should result in an even higher rate of deep (negative for MRD in conjunction with at least&#xD;
      very good partial response [VGPR] as defined by the International Myeloma Working Group&#xD;
      [IMWG]) with these responses occurring independently of cytogenetic risk. Due to potential&#xD;
      interference of elotuzumab with serum immune fixation, the investigators chose VGPR rather&#xD;
      than complete response (CR) to exclude false-positive immunofixation results. Furthermore the&#xD;
      investigators hypothesize that combining elotuzumab with lenalidomide should prolong PFS&#xD;
      further.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma (MM) is a cancer originating from the antibody-secreting plasma cell and&#xD;
      characterized by abnormal accumulation of clonal plasma cells in bone marrow. In Europe, 3.8&#xD;
      new cases of MM and 2.2 deaths per 100,000 individuals (age-standardized rate) due to MM were&#xD;
      estimated in 2012.&#xD;
&#xD;
      Treatment options for myeloma patients have markedly improved during the last decades.&#xD;
&#xD;
      For frontline treatment, high-dose myeloablative chemotherapy followed by reinfusion of&#xD;
      autologous peripheral blood stem cells has been a standard of care since 1996. Introduction&#xD;
      of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and&#xD;
      lenalidomide led to improvement in remission rates and survival in newly diagnosed patients.&#xD;
      However, high-dose chemotherapy remains essential for achievement of long-lasting remissions&#xD;
      even in the era of novel agents.&#xD;
&#xD;
      While high-dose melphalan chemotherapy (HDT) plus autologous stem cell transplant (ASCT)&#xD;
      remains a standard in eligible, medically fit subjects, defining an optimal pre- and post HDT&#xD;
      approach is subject to rapidly evolving novel-compound based options. In 2010, a group from&#xD;
      the U.S. presented results on the combination of lenalidomide, bortezomib, and dexamethasone&#xD;
      (VRd) in newly diagnosed patients with an overall response rate of 98%, however without&#xD;
      systematic consolidation by HDT. The next-generation proteasome inhibitor carfilzomib is more&#xD;
      active and very well tolerated in terms of peripheral neuropathy and gastrointestinal adverse&#xD;
      effects. A randomized phase III trial in pretreated myeloma patients found the triple regimen&#xD;
      of carfilzomib and lenalidomide/dexamethasone (Rd) to be superior to standard-Rd in terms of&#xD;
      depth of response; progression-free survival (PFS) and, most importantly, overall survival&#xD;
      (OS). At the 2015 annual meetings of the American Society of Clinical Oncology as well as the&#xD;
      European Society of Hematology, this regimen (KRd) was found to be exceptionally effective in&#xD;
      a phase 2 trial when given in newly diagnosed patients in a prolonged fashion: patients&#xD;
      received four KRd induction cycles prior to HDT. The latter was followed by an additional 4&#xD;
      consolidation and 8 maintenance cycles with KRd, followed by lenalidomide maintenance&#xD;
      thereafter. The most appealing effect was the high rate of deep remissions: stringent&#xD;
      complete response (sCR) rate increased from 22% following 4 x KRd and HDT to more than 80%&#xD;
      following all 18 cycles. Notably, the vast majority of patients in sCR also were negative for&#xD;
      minimal residual disease (MRD) as assessed by 10-color flow cytometry. MRD negativity&#xD;
      probably has a major impact on long-term disease control as was recently shown in a French&#xD;
      prospective trial investigating in the combination of VRd prior and post HDT followed by&#xD;
      lenalidomide maintenance.&#xD;
&#xD;
      Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a&#xD;
      lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III&#xD;
      trials in MM patients. One phase III trial in MM patients with one to three prior lines of&#xD;
      therapy compared elotuzumab-Rd with standard Rd. The triple combination was shown to&#xD;
      significantly prolong PFS in this patient cohort with a greater proportion of patients in at&#xD;
      least very good partial response (VGPR) when compared to subjects on Rd. Notably, the rate of&#xD;
      infusion-related reactions with this specific moAb was very low, with an overall rate of 10%&#xD;
      in premedicated patients and only 1% of Grade 3 severity. Grades 4/5 infusion-related&#xD;
      reactions were absent and only 1% of patients on elotuzumab discontinued for infusion-related&#xD;
      reactions. Of particular interest is the observation in this trial, that response and PFS&#xD;
      were independent of cytogenetic high-risk features, i.e., deletion of chromosome 17p and&#xD;
      translocation t(4;14). This effect distinguishes elotuzumab from most, if not all, other&#xD;
      drug-based approaches.&#xD;
&#xD;
      The investigators assume that incorporating the moAb into the KRd triple induction regimen&#xD;
      should result in an even higher rate of deep (negative for MRD in conjunction with at least&#xD;
      very good partial response [VGPR] as defined by the International Myeloma Working Group&#xD;
      [IMWG]) with these responses occurring independently of cytogenetic risk. Due to potential&#xD;
      interference of elotuzumab with serum immune fixation,the investigators chose VGPR rather&#xD;
      than complete response (CR) to exclude false-positive immunofixation results. Furthermore the&#xD;
      investigators hypothesize that combining elotuzumab with lenalidomide should prolong PFS&#xD;
      further.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Anticipated">August 2029</completion_date>
  <primary_completion_date type="Anticipated">August 2029</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction phase</measure>
    <time_frame>At the end of Cycle 6 (168 days for all cycles plus up to 36 days)</time_frame>
    <description>MRD negativity rate (%) as assessed by flow-cytometry in patients with VGPR or better response according to IMWG criteria following six cycles of induction treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance phase</measure>
    <time_frame>3 years from randomisation</time_frame>
    <description>Determination of progression-free survival (PFS) following randomisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of long-term efficacy (1)</measure>
    <time_frame>10 years</time_frame>
    <description>Overall response rate (%) to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of long-term efficacy (2)</measure>
    <time_frame>10 years</time_frame>
    <description>Overall survival (months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of long-term efficacy (3)</measure>
    <time_frame>10 years</time_frame>
    <description>Quality of Life (Units on Scale; Unit range from 0 to 100; Units calculated via linear transformation of raw score (RS) values from scale with single-item measure from 1 to 7 on EORTC QLQ-C30 questionnaire equivalent; Formular for transformation: Unit = {(RS-1)/6}x100)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">576</enrollment>
  <condition>Newly Diagnosed Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction/ Consolidation: Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone (E-KRd), autologous stem cell transplant, Maintenance: Elotuzumab, Lenalidomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KRd/ Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction/ Consolidation: Carfilzomib, Lenalidomide, Dexamethasone (KRd), autologous stem cell transplant, Maintenance: Lenalidomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elotuzumab</intervention_name>
    <description>i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.</description>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <other_name>Empliciti®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.</description>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <arm_group_label>KRd/ Arm B</arm_group_label>
    <other_name>Kyprolis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.</description>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <arm_group_label>KRd/ Arm B</arm_group_label>
    <other_name>Revlimid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .</description>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <arm_group_label>KRd/ Arm B</arm_group_label>
    <other_name>Fortecortin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>autologous stem cell transplant</intervention_name>
    <description>autologous stem cell transplant</description>
    <arm_group_label>E-KRd/ Arm A</arm_group_label>
    <arm_group_label>KRd/ Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible for autologous stem cell transplantation (ASCT)&#xD;
&#xD;
          -  Patient must not have been previously treated with any prior systemic therapy for the&#xD;
             treatment of multiple myeloma (only dexamethasone at a cumulative dose of 320 mg;&#xD;
             plasmapheresis/dialysis without concomitant chemotherapy,local irradiation of bone&#xD;
             lesions; and surgical intervention permitted as pretreatment)&#xD;
&#xD;
          -  Newly diagnosed multiple myeloma according to the IMWG updated criteria42: Clonal bone&#xD;
             marrow plasma cells ≥ 10% or biopsy proven bony or extramedullary plasmacytoma and any&#xD;
             one or more of the following myeloma defining events:&#xD;
&#xD;
          -  Evidence of end organ damage that can be attributed to the underlying plasma cell&#xD;
             proliferative disorder, specifically:&#xD;
&#xD;
               -  Hypercalcaemia: serum calcium &gt; 0.25 mmol/L (&gt; 1 mg/dL) higher than the upper&#xD;
                  limit of normal or &gt; 2.75 mmol/L (&gt; 11 mg/dL)&#xD;
&#xD;
               -  Renal insufficiency: creatinine clearance &lt; 40 mL per min or serum creatinine &gt;&#xD;
                  177 μmol/L (&gt; 2 mg/dL)&#xD;
&#xD;
               -  Anaemia: haemoglobin value of &gt; 2 g/dL below the lower limit of normal, or a&#xD;
                  haemoglobin value &lt; 10 g/dL&#xD;
&#xD;
               -  Bone lesions: one or more osteolytic lesions on skeletal radiography,computed&#xD;
                  tomography (CT), or PET-CT&#xD;
&#xD;
          -  Any one or more of the following markers of malignancy:&#xD;
&#xD;
               -  Clonal bone marrow plasma cell percentage ≥ 60%&#xD;
&#xD;
               -  Involved: uninvolved serum free light chain ratio ≥ 100, provided the absolute&#xD;
                  level of the involved light chain is at least 100 mg/L&#xD;
&#xD;
               -  One or more focal lesions of at least 5mm or greater in size on MRI studies&#xD;
&#xD;
          -  Measurable disease parameters as follows:&#xD;
&#xD;
          -  Serum monoclonal paraprotein (M-component) level ≥ 1 g/dL and/or urine M-protein level&#xD;
             ≥ 200 mg/24 hours or&#xD;
&#xD;
          -  In case of IgA myeloma: Serum monoclonal paraprotein level ≥ 0.5 g/dL and/or urine&#xD;
             M-protein level ≥ 200 mg/24 hours or&#xD;
&#xD;
          -  For patients with no detectable M-component: Serum FLC Assay: Involved FLC level ≥ 10&#xD;
             mg/dL (≥ 100 mg/L) provided serum FLC ratio is abnormal&#xD;
&#xD;
          -  ECOG Performance Status ≤ 2&#xD;
&#xD;
          -  Laboratory test results within these ranges:&#xD;
&#xD;
          -  White blood cell count ≥ 2 x 109/L&#xD;
&#xD;
          -  Absolute neutrophil (ANC) count ≥ 1.0 x 109/L&#xD;
&#xD;
          -  Platelet count ≥ 75 x 109/L&#xD;
&#xD;
          -  Haemoglobin &gt; 8 g/dL&#xD;
&#xD;
          -  Calculated creatinine clearance (according to MDRD) ≥ 30 mL/minute&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 x ULN&#xD;
&#xD;
          -  Corrected serum calcium level &lt; 3.5 mmol/L (&lt; 14 mg/dL)&#xD;
&#xD;
          -  Patient's legal capacity to consent to study participation&#xD;
&#xD;
          -  Patients capable to understand the purposes and risks of the study, who are willing&#xD;
             and able to participate in the study and from whom written and dated informed consent&#xD;
             to participate in the study has been obtained.&#xD;
&#xD;
          -  All females&#xD;
&#xD;
               -  must acknowledge to have understood the hazards lenalidomide can cause to an&#xD;
                  unborn fetus and the necessary precautions associated with the use of&#xD;
                  lenalidomide.&#xD;
&#xD;
               -  must use adequate contraception and agree to use two reliable forms of&#xD;
                  contraception simultaneously or to practice complete abstinence&#xD;
&#xD;
               -  must agree to have medically supervised pregnancy tests on a regular basis&#xD;
&#xD;
               -  must agree to abstain from breastfeeding while taking lenalidomide, carfilzomib&#xD;
                  and elotuzumab and for at least 28 days after the last dose of lenalidomide,&#xD;
                  carfilzomib, and elotuzumab.&#xD;
&#xD;
          -  Male subjects must&#xD;
&#xD;
               -  practice complete abstinence or use a condom during sexual contact with a&#xD;
                  pregnant female or a female with child bearing potential while taking&#xD;
                  lenalidomide, carfilzomib, and elotuzumab.&#xD;
&#xD;
               -  not donate semen or sperm&#xD;
&#xD;
          -  All subjects must&#xD;
&#xD;
               -  agree to abstain from donating blood while taking lenalidomide, during dose&#xD;
                  interruptions and for at least 28 days after the last dose of lenalidomide.&#xD;
&#xD;
               -  agree never to give lenalidomide to another person.&#xD;
&#xD;
               -  agree to return all unused lenalidomide capsules to the investigator (with&#xD;
                  exception of prescribed lenalidomide capsules)&#xD;
&#xD;
               -  be aware that no more than a 28-day lenalidomide supply may be dispensed with&#xD;
                  each cycle of lenalidomide during induction and consolidation therapy and be&#xD;
                  prescribed during maintenance therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy,&#xD;
&#xD;
          -  monoclonal protein, and skin changes)&#xD;
&#xD;
          -  Waldenström's macroglobulinemia or IgM myeloma&#xD;
&#xD;
          -  Plasma cell leukemia (&gt; 2.0 x 109/L circulating plasma cells by standard differential&#xD;
             blood count)&#xD;
&#xD;
          -  Pregnant, breast-feeding females, FCBPs and males who are unwilling to comply with the&#xD;
             lenalidomide Pregnancy Prevention Risk Management Plan.&#xD;
&#xD;
          -  Patients with high cardiovascular risk, including but not limited to history of&#xD;
             myocardial infarction or coronary stenting in the past 6 months; NYHA Class III or IV&#xD;
             heart failure, uncontrolled angina, uncontrolled hypertension, severe uncontrolled&#xD;
             arrhythmias&#xD;
&#xD;
          -  Prior cerebral vascular accident (CVA) with persistent neurological deficit&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Known HIV-seropositivity, active or chronic hepatitis A, B, C or D-infection&#xD;
             (including patients who are tested anti-HBC positive and/or HBsAg positive).&#xD;
&#xD;
          -  Any other severe concomitant disease or disorder, including the presence of laboratory&#xD;
             abnormalities, which places the subject at unacceptable risk or which could influence&#xD;
             patient's ability to participate in the study and his/her safety during the study or&#xD;
             interfere with interpretation of study results.&#xD;
&#xD;
          -  Greater or equal to Grade 2 peripheral neuropathy on clinical examination within 14&#xD;
             days before enrollment&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to randomization&#xD;
&#xD;
          -  Any systemic anti-myeloma therapy within 4 weeks of randomization except a max.&#xD;
             cumulative dose of 320 mg auf dexamethasone.&#xD;
&#xD;
          -  Any prior or concurrent malignancy other than multiple myeloma.&#xD;
&#xD;
          -  Exceptions include patients who have been disease-free for at least five years before&#xD;
             study entry or patients with adequately treated and completely resected basal cell or&#xD;
             squamous cell skin cancer, in situ cervical, breast or prostate cancer.&#xD;
&#xD;
          -  Known hypersensitivity to carfilzomib, lenalidomide, and elotuzumab or to any of the&#xD;
             excipients of carfilzomib, lenalidomide, and elotuzumab or to any other component of&#xD;
             any study drug formulation&#xD;
&#xD;
          -  Participation in any other clinical trial or treatment with any experimental drug or&#xD;
             other experimental therapy within 28 days before enrolment to the study or during&#xD;
             study participation until the end of treatment visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Knop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuezburg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hermann Einsele, MD</last_name>
    <phone>+49 (0)931 201</phone>
    <phone_ext>40001</phone_ext>
    <email>Einsele_H@ukw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Knop, MD</last_name>
    <phone>+49 (0)931 201</phone>
    <phone_ext>40013</phone_ext>
    <email>Knop_S@ukw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Univ. Klinikum Krems</name>
      <address>
        <city>Krems</city>
        <state>Lower Austria</state>
        <zip>A-3500</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Podar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum St. Pölten</name>
      <address>
        <city>St. Polten</city>
        <state>Lower Austria</state>
        <zip>A-3100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Pichler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH-Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siegfried Sormann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Normann Steiner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>A-4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Schmitt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen</name>
      <address>
        <city>Wels</city>
        <state>Upper Austria</state>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kühr, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH Rankweil-Feldkirch</name>
      <address>
        <city>Rankweil</city>
        <state>Vorarlberg</state>
        <zip>A-6830</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Hartmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Greil, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AKH Meduni Wien</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermine Agis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Ottakring</name>
      <address>
        <city>Vienna</city>
        <zip>A-1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niklas Zojer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Engelhardt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Ostalb</name>
      <address>
        <city>Mutlangen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Hebart, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Dechow, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonieklinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Greiner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette Hoferer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Kull, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologie Schwarzwald-Alb</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Köchling, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gesundgheitszentrum St. Marien</name>
      <address>
        <city>Amberg</city>
        <state>Bavaria</state>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludwig Fischer von Weikersthal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <state>Bavaria</state>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Hackanson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sozialstiftung Bamberg</name>
      <address>
        <city>Bamberg</city>
        <state>Bavaria</state>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Seggewiß-Bernhardt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <state>Bavaria</state>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Kiani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten-Oberallgäu</name>
      <address>
        <city>Kempten</city>
        <state>Bavaria</state>
        <zip>87439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Langer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80634</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Hentrich, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Theurich, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Bassermann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nuremberg</city>
        <state>Bavaria</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Schäfer-Eckart, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albrecht Reichle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <state>Bavaria</state>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Zettl, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg, Medizinische Klinik II</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bavaria</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Knop, MD</last_name>
      <phone>+49 (0)931 201</phone>
      <phone_ext>40013</phone_ext>
      <email>Knop_S@ukw.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt</city>
        <state>Hesse</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana von Metzler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Jung, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med. Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Könecke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <state>Lower Saxony</state>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Metzner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Pomerania</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian-Andreas Schmidt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Pomerania</state>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Böttcher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken</name>
      <address>
        <city>Schwerin</city>
        <state>Mecklenburg-Pomerania</state>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Günther, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Klinikum Bethel</name>
      <address>
        <city>Bielefeld</city>
        <state>North Rhine-Westphalia</state>
        <zip>33611</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Weißinger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital</name>
      <address>
        <city>Dortmund</city>
        <state>North Rhine-Westphalia</state>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Meyer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Barbara-Klinik Hamm</name>
      <address>
        <city>Hamm</city>
        <state>North Rhine-Westphalia</state>
        <zip>59075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz Dürk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Reusch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Marien-Krankenhaus</name>
      <address>
        <city>Siegen</city>
        <state>North Rhine-Westphalia</state>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Naumann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftsklinikum Mittelrhein</name>
      <address>
        <city>Koblenz</city>
        <state>Rhineland-Palatinate</state>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Breitbarth-Girmscheid, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Saxony-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kinga Ligeti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Saxony-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Wolleschak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolin Trautmann-Grill, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Pönisch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus</name>
      <address>
        <city>Flensburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helge Menzel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Schub, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svenja Kopelke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <state>Thuringia</state>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekkehard Eigendorff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Friedrich-Schiller-Universität Jena</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie von Lilienfeld-Toal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor-Wolfgang Blau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Fuhrmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>13585</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annegret Kunitz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Bormann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Salwender, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>autologous stem cell transplant</keyword>
  <keyword>Elotuzumab</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Elotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

